Genital Herpes-Pipeline Insights, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 84743
Related Topics: FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Genital
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s, “ Genital Herpes-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Genital Herpes. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Genital Herpes. DelveInsight’s Report also assesses the Genital Herpes therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

• The report provides competitivepipeline landscape of Genital Herpes

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Genital Herpes pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Genital Herpes and also provide company profiling

• The report also gives the information of dormant and discontinued pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time - 48-72 Hours

Table of Contents
for Genital Herpes-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Genital Herpes-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Genital Herpes, 2017

• Number of Products under Development by Companies

• Comparative Analysis by Filed and Phase III Products, 2017

• Comparative Analysis Phase II Products, 2017

• Comparative Analysis Phase I and IND Filed Products, 2017

• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017

• Drug Candidates Profiles

• Genital Herpes Assessment by Monotherapy Products

• Genital Herpes Assessment by Combination Products

• Genital Herpes Assessment by Route of Administration

• Genital Herpes Assessment by Stage and Route of Administration

• Genital Herpes Assessment by Molecule Type

• Genital Herpes Assessment by Stage and Molecule Type

• Genital Herpes Therapeutics – Discontinued Products

• Genital Herpes Therapeutics – Dormant Products

• Products under Development by Companies, 2017

List Of Figures, Charts and Diagrams
in Genital Herpes-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Genital Herpes, 2017

• Filed and Phase III Products, 2017

• Phase II Products, 2017

• Phase I and IND Filed Products, 2017

• Discovery and Pre-Clinical Stage Products, 2017

• Genital Herpes Assessment by Monotherapy Products

• Genital Herpes Assessment by Combination Products

• Genital Herpes Assessment by Route of Administration

• Genital Herpes Assessment by Stage and Route of Administration

• Genital Herpes Assessment by Molecule Type

• Genital Herpes Assessment by Stage and Molecule Type

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

84743 | DIPR2017257

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Genital Herpes - Epidemiology Forecast To 2023
DelveInsight “Genital Herpes - Epidemiology Forecast To 2023” provides an overview of the epidemiolo...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Genital Herpes-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Genital Herpes - Market Ins...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017
DelveInsight’s, “ Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017”, report provides in...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landsc...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Herpes - Pipeline Review, H1 2017
Genital Herpes - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and He...
22 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016
Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Global Clinical Trials Review, H1, 2016
Genital Herpes Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Ge...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Treatment Market: By Product type (Acyclovir, Famciclovir, Valacyclovir), By Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores) & Geography -Forecast (2016-2021)
General herpes is categorised as a sexually transmitted disease/infection (STI) which is caused by h...
18 Feb 2016 by USD $4,463 (normally
USD $5,251)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...